After a few months, the Cervavac cervical cancer vaccine developed in the country will be available. As announced by the Government, it will be launched in the next few months. Its price will also be lower i.e. 200-400 rupees.

Cervical cancer is the second most common cancer in India. India accounts for approximately one-fourth of all cervical cancer deaths worldwide. According to current statistics, around 1.25 million women are diagnosed with cervical cancer every year.

More than 75,000 people die from this disease in India. In India, 83 percent of cervical cancers are caused by HPV 16 or 18, while 70 percent of women worldwide suffer from this virus. A quadrivalent human papillomavirus (QHPV) vaccine will be developed under the leadership of Adar C Poonawalla, executive director of the Serum Institute of India.

what is hpv

HPV, or human papilloma virus, is a dangerous virus that spreads the fastest. In most cases, the symptoms of the disease caused by this virus are not even known. Therefore, it is also not known that this virus present in someone infects their partner.

yThe virus spreads through contact between the genital organ and the skin of the anus. This virus can spread between two people even without sexual penetration.

Up to 80 percent of sexually active women and men are infected with the virus at some point in their lives. According to Adar C Poonawalla, The human papillomavirus (HPV) vaccine may be the only way to prevent cervical cancer.

It is estimated that HPV types 16 and 18 (HPV-16 and HPV-18) together account for about 70 percent of all invasive cervical cancer cases worldwide.

The trial is ongoing even with a single dose of the vaccine

The first indigenously developed quadrivalent human papillomavirus (QHPV) vaccine will be launched in a few months. Using this vaccine can reduce 85 to 90 percent of cervical cancer cases. This will save the lives of thousands of women.

Initially, this vaccine will come in two doses. An investigation into the administration of his single dose vaccine is also underway. Therefore, in the future, it might be possible to prevent cervical cancer with a single dose of the indigenous vaccine.

However, clinical trials have been conducted in India for the effect of a single dose of the US-made quadrivalent cervical cancer vaccine. In this case, a single dose of this foreign vaccine was found to be 95.4 percent effective in preventing genotype 16 and 18 cervical cancer. A research paper on this trial was published in the international medical journal Lancet.

The Survek vaccine will be developed in partnership with the Serum Institute of India

Department for Vaccine Biotechnology “SERVAC”. (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) in cooperation with the Bill & Melinda Gates Foundation. She was supported by the Serum Institute of India through its partnership program ‘Grand Challenges India’ for indigenous development of a quadrivalent vaccine.

Previously, the world’s first DNA vaccine for Covid-19 was developed by Cadila Healthcare in its country, which received approval for emergency use on August 20, 2021. This is the first mRNA vaccine in the country and an intranasal vaccine against Kovid-19.